This tool allows subscribers to track the progress of share prices belonging to all of the key listed animal health companies.
Aratana Therapeutics' share price recently fell to its lowest value since February 2016.
Zoetis is seeking an additional European approval for Stronghold Plus under a different brand name.
Aratana Therapeutics reported a 53% drop in sales to $4.9 million during the fourth quarter of 2018, due to a large one-off payment made last year.
Heska has appointed Mark Furlong to its board of directors, bringing in key financial know-how.
Kindred Biosciences is looking at various commercial options as it aims for approval of its first product in Europe this year.
Zoetis has launched the first commercial genomic test created exclusively for Jersey cattle in the US.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.